Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 167, Issue 1-2, Pages 131-137Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2005.05.016
Keywords
multiple sclerosis; myelin autoantibodies; glycosylated antigen; diagnosis; B cell; autoimmunity
Categories
Ask authors/readers for more resources
Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors (BDs), 25 patients affected by meningitis/encephalitis, 41 affected by systemic lupus erythematosus (SLE) and 49 affected by rheumatoid arthritis (RA). The IgM antibody level to CSF114(Glc) was significantly increased in MS patients versus BDs (p<0.001) or versus other autoimmune diseases (SLE or RA, p<0.001). The IgG response was restricted to the subclass IgG2. IgM antibodies to CSF114(Glc) were found in 30% of relapsing/remitting MS patients and, at lower levels, in subjects affected by meningitis/encephalitis. The study of antibodies to CSF114(Glc) is a new, potential immunological marker of MS. (C) 2005 Elsevier B.V.. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available